The results suggested that both doses of AM were able to ameliorate the expression of fibrotic indicators in the mesenterium of model mice by modulating the AR/TGF-β1/smads pathway, prompting a therapeutic effect on PF. The gene discussed is TGFB1; the disease is pemphigus foliaceus.